Kanvas Biosciences
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
$48MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy